Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Dr Kashyap Patel Discusses the Importance of WES in Reducing Targeted Treatment Disparities
June 4th 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Read More
Dr Enrique Ocio Discusses the Advantages of Sub-Q Isatuximab for RRMM
June 4th 2022Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).
Read More
ASCO, WHO to Launch Global Quality Initiative in Cancer Care
June 4th 2022The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.
Read More
Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%
June 4th 2022Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Read More
ASCO Returns to Chicago, With Health Equity and Innovation on the Agenda
June 2nd 2022For the second year, the meeting will focus on health equity, as American Society of Clinical Oncology (ASCO) President Everett Vokes, MD, FASCO, has selected the theme “Advancing Equitable Cancer Care Through Innovation.”
Read More
Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone
June 1st 2022Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.
Read More
Dr Kashyap Patel Updates on Exciting Developments at ASCO22
June 1st 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Nivolumab-Based Combos Approved in First-line Advanced ESCC
May 28th 2022The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.
Read More
Increased Social Spending by States Linked to Improved OS for Black Patients With Cancer
May 26th 2022Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.
Read More
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.
Read More
Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer
May 9th 2022Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
Read More
European Effort Will Make Cholangiocarcinoma Treatment Info Available in Multiple Languages
May 2nd 2022The project seeks to develop materials explaining chemotherapy regimens for patients with biliary tract cancers and then translate these materials into “standardized, high-quality, free, and easily accessible resources."
Read More
City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different
April 17th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.
Read More
Dr Debra Patt Discusses Considering Strategies for Additional COVID-19 Boosters in Breast Cancer
April 16th 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.
Read More
Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study
April 16th 2022The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.
Read More
Evidence, Support, and Education Needed to Drive Precision Oncology, Accenture’s Bogdan Says
April 14th 2022Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.
Read More
OneOncology’s Arrowsmith Looks Forward to Real-time Dynamics in Clinical Pathways
April 14th 2022Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.
Read More
Preclinical Data at AACR Show CSP May Be Broad Target in Cholangiocarcinoma
April 13th 2022Researchers presented results for ZB131, a monoclonal antibody that would target cancer-specific plectin (CSP); experiments with mice showed this may be present in more than 80% of the most common types of cholangiocarcinoma.
Read More